Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin

Details for Australian Patent Application No. 2010323068 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Dugi, Klaus; Graefe-Mody, Eva Ulrike; Mark, Michael; Woerle, Hans-Juergen; Zimdahl-Gelling, Heike

Agent Spruson & Ferguson

Pub. Number AU-A-2010323068

PCT Pub. Number WO2011/064352

Priority 09177418.2 27.11.09 EP; 10166714.5 21.06.10 EP

Filing date 26 November 2010

Wipo publication date 3 June 2011

International Classifications

A61K 31/155 (2006.01) - Amidines (), e.g. guanidine (HNC(NH)NH), isourea (HNC(OH)NH), isothiourea (HNC(SH)NH)

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

3 May 2012 PCT application entered the National Phase

  PCT publication WO2011/064352 Priority application(s): WO2011/064352

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010323071-Polymorphous forms III and IV of Nbenzoyl staurosporine

2010323066-Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders